on behalf of the ALBIOS Study Investigators BACKGROUND: The biological role of adrenomedullin (ADM), a hormone involved in hemodynamic homeostasis, is controversial in sepsis because administration of either the peptide or an antibody against it may be beneficial.
Since its discovery in 1993, 1 the 52-amino acid peptide adrenomedullin (ADM) has been implicated in the pathobiology of several diseases, including cardiovascular disorders. 2 ADM is indeed up-regulated in different tissues as well as in several conditions, in association, among others, with myocardial injury, systemic inflammatory response syndrome, shock, cellular hypoxia, and oxidative stress. In addition, remarkably high circulating levels of ADM have been reported in sepsis, 3 where its role remains controversial. 4 On one hand, during sepsis, ADM can exert beneficial effects by reducing endothelial hyperpermeability and vascular leakage, as shown in cell culture models. [5] [6] [7] Indeed, exogenous administration of ADM appears to be protective in animal models of endotoxin 8 and a-toxin infusion, 6 or ARDS. 9 On the other hand, it is well known that higher circulating levels of ADM are invariably associated with worse outcomes. [10] [11] [12] [13] Moreover, administration of anti-ADM antibodies can attenuate sepsis-induced multiple organ failures in murine models, [14] [15] [16] and a humanized monoclonal anti-ADM antibody is under clinical development. 17 Several factors may be at the interplay of such apparent paradox, such as differences in the circulating levels of ADM, the specific type of experimental model used, the stage of the disease, and the underlying co-morbidities and co-interventions in clinical settings.
The interpretation of ADM as a biomarker is difficult because several fragments of the precursor prohormone circulate in blood and do not necessarily reflect the activity of ADM. A sandwich immunoassay for specifically measuring the biologically active (amidated) form of ADM (named bioactive ADM or bio-ADM) has been developed. 18 By using these reagents, bio-ADM levels in patients being evaluated at the ED for acute heart failure were shown to be predictive of clinically relevant 30-day outcomes. 19 In a monocentric study performed on 101 consecutive patients presenting at the ED with the suspicion of sepsis, Marino et al 18 observed
that bio-ADM levels were associated with short-term mortality and vasopressor requirement.
Here we aimed at testing, for the first time, this biomarker in a large and well-defined cohort of patients with severe sepsis or septic shock, enrolled in the biomarker substudy of the Albumin Italian Outcome Sepsis (ALBIOS) trial. 20 Given the biological role of ADM in fluid homeostasis and systemic circulation, and the profound pathophysiologic perturbations seen in the early phase of sepsis and during its treatment, we were particularly interested in describing the relation between bio-ADM and hemodynamic support requirements during the first days of treatment. In addition, we described bio-ADM trajectory over time and its prognostic value for 90-day mortality.
Materials and Methods

Study Design
ALBIOS was a multicenter, pragmatic, open-label, randomized trial that enrolled 1,818 patients with severe sepsis or septic shock admitted to 100 ICUs. Study design, inclusion and exclusion criteria, and main results have been published elsewhere. 20 The study complied with the 1975 Declaration of Helsinki as revised in 2008 and was approved by the institutional review board of each center. Written informed consent or deferred consent was obtained from each participant, according to the Italian legislation.
A detailed description of data collection procedures, clinical definitions and statistical methods can be found in e-Appendix 1.
Sample Collection and Circulating Biomarker Measurements
In a subset of 956 patients recruited from 40 centers participating in a predefined biomarker substudy, venous blood samples were serially collected 1, 2, and 7 days after enrolment (or at ICU discharge, whichever came first) and centrifuged; plasma was then shipped on dry ice to a central repository and stored at À70 C until assayed. The bio-ADM was measured using a chemiluminescence immunoassay provided by Sphingotec GmbH. 18 The assay sensitivity is 2 pg/mL. In prior work, 18 the median bio-ADM concentration of 200 healthy adults equaled 20.7 pg/mL, with a 99th percentile of 43.0 pg/mL.
Results
Variables Associated With bio-ADM Levels
Median concentration of bio-ADM on day 1 was 110 pg/mL (interquartile range, 59-198) (n ¼ 956). Table 1 Dr Cavana is currently working at Ospedale S. Chiara -Dipartimento di Anestesia e Rianimazione/Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento, Trento, Italy. shows patients' demographic and baseline characteristics according to tertiles of bio-ADM concentrations on the same day. By multiple linear regression analysis, the variables most strongly associated with higher bio-ADM concentrations, were, by decreasing order of r 2 , higher sequential organ failure assessment (SOFA) score (F ¼ 31, P < .0001), ICU admission after emergency surgery (F ¼ 15, P < .0001), higher heart rate (F ¼ 21, P < .0001), higher serum creatinine levels (F ¼ 17, p<0.0001), higher central venous pressure (F ¼ 16, P ¼ .0001), lower serum albumin concentration (F ¼ 14, P ¼ .0002), positive blood culture (F ¼ 7, P ¼ .001), lower mean arterial pressure (F ¼ 13, P ¼ .0003), higher BMI (F ¼ 12, P ¼ .0005), and immunodeficiency (F ¼ 11, P ¼ .001).
bio-ADM, Hemodynamic Goals, and Support Requirements
Higher concentrations of bio-ADM on day 1 were associated with less frequent achievement of hemodynamic goals during the first 6 to 24 hours after randomization in terms of central venous pressure and oxygen saturation, mean arterial pressure, and serum lactate concentrations (e- Table 1 ). Patients in the upper tertile of bio-ADM more frequently received two or more vasoactive drugs and showed higher values of inotropic score and vasopressor dependency index compared with the middle and the lower tertiles (e- Table 1 ). As shown in Figure 1 , the inotropic score over the first 7 days of treatment in patients alive at that time was greater in those with higher levels of bio-ADM at day 1 compared with those with lower levels. In parallel, serum lactate levels were significantly higher in patients in the upper tertile (Fig 1) . Moreover, patients in the upper tertile of bio-ADM also showed greater need of fluids during the first week of treatment, as shown by the average fluid administered, the average amount of albumin or crystalloids received, and the average and the cumulative fluid balances observed over the first 7 days (e- Table 1 ).
bio-ADM and Organ Failures
Prevalent and incident organ failures, defined as organspecific SOFA scores of 3 or 4 for the respiratory, coagulation, and hepatic and renal systems, were more frequent at higher concentrations of bio-ADM on day 1 (e- Fig 1) . Accounting for multiple organ failures and death, we observed elevated bio-ADM levels in patients with multiple prevalent or multiple incident organ failures and in those who died during the follow-up period.
bio-ADM and Septic Shock
Patients presenting with septic shock at the time of enrollment had significantly higher concentrations of bio-ADM than those with severe sepsis only (P < .0001) and showed a greater reduction over the first 7 days compared with patients without shock (P for interaction time Â shock < .0001; e- Fig 2) .
Among patients without shock at study entry, there was a progressive increase in the likelihood of having incident shock with higher concentrations of bio-ADM (e -Fig 3) , which remained significant after adjustments for the Simplified Acute Physiology Score II or for clinically relevant variables (e- Table 2 ).
bio-ADM and 90-Day Mortality
During 90 days of follow-up, 369 patients (38.6%) died. Main clinical characteristics of survivors and nonsurvivors are shown in e- Table 3 . e- Figure 4 shows the Kaplan-Meier mortality at 90 days by tertiles of chestjournal.org bio-ADM concentrations on day 1, with a clear, stepwise increment of the risk of mortality with increasing bio-ADM levels. The progressive relationship between bio-ADM concentrations on day 1 and 90-day mortality (with a 1.9-fold relative increase in event rate from the lower to the upper tertile), was confirmed by restrictive spline curves (e- Fig 5) .
In Cox proportional hazard models adjusted for clinically relevant covariates, bio-ADM concentrations on day 1 remained independently associated with 90-day mortality in the overall cohort (Table 2) .
Time Course of bio-ADM and 90-Day Mortality
To evaluate the association between the variation over time of bio-ADM and short-term mortality, we analyzed bio-ADM time course over the first 7 days by mortality after this period. bio-ADM decreased over the first 7 days after randomization in the subgroup of patients surviving the first week of treatment, whereas it remained stable in those dying (P for interaction between time and mortality < .0001, e- Fig 6) . Figure 2 shows the Kaplan-Meier survival curves for 90-day mortality according to the evolution of bio-ADM levels from day 1 to day 7, stratified according to the median concentration of bio-ADM on day 1 (110 pg/mL).
Patients with bio-ADM concentrations decreasing from above the median value on day 1 to below the median value on day 7 showed a 90-day mortality rate close to those with bio-ADM remaining below the median value at both time points (33.3 vs 26.7%, Fig 2) . In contrast, outcome was markedly worse and comparable both in patients with increasing bio-ADM concentrations over time (66.7%) and in those with higher bio-ADM levels at both time points (64.6%). In time-dependent Cox regression models adjusted for clinically relevant covariates, evolution of bio-ADM concentrations over the first 7 days was independently associated with 90-day mortality (Fig 3) .
bio-ADM and Other Clinical Outcomes
Finally, higher concentrations of bio-ADM on day 1 were associated with further clinically relevant outcomes (e- Table 4 ). Of note, after adjustments, patients with higher levels of bio-ADM at day 1 showed longer length of hospital stay and a higher incidence of renal replacement therapy during the study period (P <.01, for both) compared with patients with lower levels of bio-ADM.
Randomized treatment (albumin or crystalloids vs crystalloids alone) had no effect on bio-ADM concentrations over time (e- Table 5 ). Evolution of the inotropic score (A) and serum lactate concentrations (B) over the first 7 days after enrollment in patients alive at 7 days, according to tertiles of bio-ADM concentrations on day 1. The inotropic score was calculated each day as follows (30):
wherein all doses are expressed as mg/kg/min. See Methods for further details. *P < .01 across tertiles of bio-ADM by linear regression analysis.
After adjustment for the simplified acute physiologic score II score, P < .05 at day 1 and day 2 for inotropic score; P # .01 from day 1 to day 7 for serum lactate. bio-ADM ¼ bioactive adrenomedullin.
Discussion
In our study, we showed that (1) plasma concentration of bio-ADM was high, especially in patients with septic shock; (2) higher bio-ADM on day 1 predicted the intensity of the hemodynamic support requirement over the first week of treatment; (3) bio-ADM predicted incident organ-specific failure and shock; and (4) bio-ADM's trajectory over the first week was 183 (70) 10 (20) 87 (133) 321 (120) 168 (84) 10 (20) 76 (144) 
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No shock Shock All patients Figure 3 -Time-dependent bio-ADM concentration predicts 90-day mortality. Association between time-dependent bio-ADM concentration from day 1 to day 7 and 90-day mortality in the entire study population and by the presence or absence of shock at the time of enrollment. Timedependent bio-ADM concentration from day 1 to day 7 was entered as a linear variable in univariate (square) or multivariable (circle) models. The model included time-dependent bio-ADM, age, sequential organ failure assessment score, serum lactate concentration, and central venous oxygen saturation at baseline. 20 HR interval for an increase of 1 interquartile range of time-dependent bio-ADM concentration. HR, hazard ratio. See Figure 1 legend for expansion of other abbreviation.
chestjournal.org strongly and independently associated with 90-day mortality. ADM exerts multiple effects with possible clinical importance, such as vasodilation, diuresis, and natriuresis. 21 Despite its importance in the pathophysiology of sepsis, 22 experimental findings seem controversial: two apparently opposite interventions, exogenous administration of the peptide or modulation with antibodies directed against the same peptide, produce benefits in preclinical sepsis models. 4 The design of the present study is not ideal for providing mechanistic insights into the role of ADM in sepsis. We confirm that the biologically active ADM circulates in elevated concentrations during severe sepsis and septic shock. In previous studies, ADM levels have been estimated either with a competitive radioimmunoassay with technical limitations, 10 with an assay of unknown analytical performance, 13 or by measuring an inactive, stable fragment of pro-ADM. 11, 12 Because the activity of ADM depends on the conversion of the C-terminal glycine residue to an amide and because amidation rate differs among pathological states, 23, 24 the levels measured in the present study are very likely to better reflect the biological relevance of ADM in sepsis.
Aggressive fluid therapy and hemodynamic support to restore peripheral organ perfusion based upon predefined hemodynamic targets are the cornerstone of the management of patients with sepsis. 25 Despite these standardized procedures, several experimental and clinical evidence suggest that this approach may have harmful effects, and should be individualized. [26] [27] [28] [29] [30] Because instrumental and laboratory measurements may have incomplete value in guiding individual hemodynamic support requirement, [31] [32] [33] [34] we sought to investigate whether a simple, objective measurement of a circulating biomarker early in the clinical course of sepsis could predict the subsequent need for fluids or vasopressors administration. We indeed observed that higher bio-ADM levels on day 1 predicted more positive fluid balance and higher doses of vasopressor agents administered during the first 7 days of treatment, independently on the overall patient severity. In the same cohort of patients, we previously showed that plasma concentrations of a natriuretic peptide were extremely elevated, up to levels normally encountered during acute heart failure. 35 We speculate that these levels may reflect excessive fluid administration in the early phase of the treatment of sepsis, resulting in high atrial and ventricular filling pressures, which are the main determinants of cardiac release of natriuretic peptides. 36 Taken together, our findings show a clear association between the up-regulation of a biomarker of an endocrine system controlling fluid homeostasis and vasodilation with fluid overloading as well as the intensity of hemodynamic support applied during severe sepsis and septic shock. It remains to be formally demonstrated, however, in appropriately designed, prospective clinical studies, that bio-ADM levels may be targeted by adjusting fluid therapy or vasopressors in sepsis, with a favorable effect on outcomes.
Higher levels of bio-ADM on day 1 predicted incident shock. Moreover, patients with early elevated bio-ADM had a higher proportion of organ dysfunction or failures. Of note, after correction for competing risks between the copresence of multiorgan failures or the subsequent development of death, we found an independent association between bio-ADM and multiple prevalent or incident organ failures and with the subsequent development of death during follow-up. Taken together, these results highlight the role of bio-ADM as an early indicator of an increased risk of sepsis-related morbidity and mortality. Our findings also support two clinically relevant aspects that merit further discussion. First, early bio-ADM monitoring may guide toward a timely implementation and monitoring of an adequate hemodynamic support in those patients who are likely to develop subsequently overt cardiovascular dysfunction. Indeed, similar to what has been observed for the initiation of antimicrobial therapy, 37, 38 evidence has shown an increased risk of death for each hour delay in the initiation of vasopressor therapy during septic shock. 39 Second, because of the key role of the cardiovascular system in the pathophysiology of sepsis and septic shock, bio-ADM may appear as a novel candidate for a targeted therapy of sepsis, aimed at blunting its excessive effects.
The trajectory of bio-ADM over the first 7 days after the diagnosis of severe sepsis or septic shock was a strong indicator of subsequent mortality. We also confirm the prognostic value of repeated measurements of bio-ADM, even at 70 pg/mL, a different cutoff previously identified in an independent cohort of 101 consecutive patients admitted to the ED with suspected sepsis (e -Fig 7) . 18 The association between time-dependent bio-ADM variation and outcome was independent of the more robust risk factors commonly observed in patients with sepsis, and already tested in the original ALBIOS trial 20 (ie, age, total SOFA score, serum lactate concentration, and central venous oxygen saturation). Consequently, bio-ADM may be considered a good candidate for early risk stratification in patients with sepsis or septic shock. Moreover, our data suggest that the sequential assessment of bio-ADM may be important to monitor the efficacy of the hemodynamic treatment applied, which may be targeted to obtain a reduction of bio-ADM levels (ie, to a level lower than 110 pg/mL).
The present study has some limitations. First, ALBIOS was a pragmatic trial, and circulating biomarkers were assessed first on the morning after enrollment; therefore, bio-ADM levels on day 1 might have been affected by early study treatment. Nonetheless, the availability of plasma samples at later time points (over the first week of treatment) allows the evaluation of the time course of the biomarkers with a reasonable accuracy during the first critical phase of the treatment of sepsis. Second, because only a relative small percentage of patients initiated vasopressor therapy after day 1, the present study can only provide indication on the potential of bio-ADM as an early predictor of fluid requirement, or as an indicator of the response to vasopressor administration. Further studies in large cohorts of patients with the suspicion of sepsis and without shock are necessary to further elucidate this hypothesis.
Conclusions
We showed in a large and representative cohort of acutely ill patients with severe sepsis or septic shock that the circulating, biologically active form of adrenomedullin is extremely elevated. The strict association between early bio-ADM levels and subsequent development of multiple organ dysfunctions and death, in addition to hemodynamic support requirement, denotes an important role of bio-ADM in the pathophysiology of sepsis and septic shock. It remains to be demonstrated whether it will be valuable for clinical monitoring of fluid and vasopressor requirements to individualize an adequate hemodynamic support therapy and avoid potentially harmful effects.
